PortfoliosLab logoPortfoliosLab logo
Bio-Rad Laboratories, Inc. (BIO)
Performance
Return for Risk
Dividends
Drawdowns
Volatility
Financials

Company Info

ISIN
US0905722072
CUSIP
090572207
IPO Date
Jan 1, 1966

Highlights

Market Cap
$7.53B
Enterprise Value
$8.20B
EPS (TTM)
$28.09
PE Ratio
9.92
PEG Ratio
0.09
Total Revenue (TTM)
$2.58B
Gross Profit (TTM)
$1.34B
EBITDA (TTM)
$288.60M
Year Range
$211.43 - $343.12
Target Price
$337.50
ROA (TTM)
7.18%
ROE (TTM)
10.20%

Share Price Chart


Loading graphics...

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Bio-Rad Laboratories, Inc.

Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in Bio-Rad Laboratories, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


Loading graphics...

S&P 500 Index

Returns By Period

Bio-Rad Laboratories, Inc. (BIO) has returned -8.00% so far this year and 14.45% over the past 12 months. Over the last ten years, BIO has returned 7.17% per year, falling short of the S&P 500 Index benchmark, which averaged 12.16% annually.


Bio-Rad Laboratories, Inc.

1D
3.10%
1M
0.11%
YTD
-8.00%
6M
-0.58%
1Y
14.45%
3Y*
-16.51%
5Y*
-13.63%
10Y*
7.17%

Benchmark (S&P 500 Index)

1D
2.91%
1M
-5.09%
YTD
-4.63%
6M
-2.39%
1Y
16.33%
3Y*
16.69%
5Y*
10.18%
10Y*
12.16%
*Multi-year figures are annualized to reflect compound growth (CAGR)

Monthly Returns

Based on dividend-adjusted daily data since Feb 27, 1980, BIO's average daily return is +0.06%, while the average monthly return is +1.33%. At this rate, your investment would double in approximately 4.4 years.

Historically, 55% of months were positive and 45% were negative. The best month was Sep 1980 with a return of +46.5%, while the worst month was Mar 1980 at -66.2%. The longest winning streak lasted 9 consecutive months, and the longest losing streak was 6 months.

On a daily basis, BIO closed higher 45% of trading days. The best single day was Oct 21, 1987 with a return of +21.1%, while the worst single day was Mar 18, 1980 at -50.0%.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
2026-3.07%-5.20%0.11%-8.00%
20259.85%-26.52%-8.15%0.21%-7.03%6.34%0.26%23.12%-5.87%13.97%1.66%-6.73%-7.77%
2024-0.62%1.56%6.13%-22.01%6.34%-4.79%23.89%-0.31%-0.81%7.06%-4.93%-3.53%1.74%
202311.17%2.22%0.25%-5.89%-17.18%1.55%6.92%-1.27%-10.43%-23.20%10.77%5.89%-23.21%
2022-20.63%4.37%-10.02%-9.09%5.02%-7.96%13.79%-13.89%-14.00%-15.69%17.91%1.39%-44.35%
2021-1.57%1.87%-2.28%10.32%-4.41%6.96%14.78%8.83%-7.31%6.53%-5.22%0.31%29.61%

Benchmark Metrics

Bio-Rad Laboratories, Inc. has an annualized alpha of 7.83%, beta of 0.69, and R² of 0.13 versus S&P 500 Index. Calculated based on daily prices since February 28, 1980.

  • Beta of 0.69 may look defensive, but with R² of 0.13 this stock is largely uncorrelated with S&P 500 Index — low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
  • R² of 0.13 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

Alpha
7.83%
Beta
0.69
0.13
Upside Capture
101.68%
Downside Capture
102.34%

Return for Risk

Risk / Return Rank

BIO ranks 52 for risk / return — on par with similar stocks. You're getting a typical balance of risk and reward. Not a standout, but not a red flag either — a reasonable choice if other factors align with your goals.


BIO Risk / Return Rank: 5252
Overall Rank
BIO Sharpe Ratio Rank: 5353
Sharpe Ratio Rank
BIO Sortino Ratio Rank: 5050
Sortino Ratio Rank
BIO Omega Ratio Rank: 4949
Omega Ratio Rank
BIO Calmar Ratio Rank: 5555
Calmar Ratio Rank
BIO Martin Ratio Rank: 5656
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

Return / Risk — by metrics

The table below present risk-adjusted performance metrics for Bio-Rad Laboratories, Inc. (BIO) and compare them to a chosen benchmark (S&P 500 Index).


BIOBenchmarkDifference

Sharpe ratio

Return per unit of total volatility

0.34

0.90

-0.56

Sortino ratio

Return per unit of downside risk

0.84

1.39

-0.55

Omega ratio

Gain probability vs. loss probability

1.11

1.21

-0.11

Calmar ratio

Return relative to maximum drawdown

0.60

1.40

-0.80

Martin ratio

Return relative to average drawdown

1.47

6.61

-5.14

Explore BIO risk-adjusted metrics in detail

Dive deeper into individual metrics with historical trends, benchmark comparisons, and performance across different time periods.

Dividends

Dividend History


Bio-Rad Laboratories, Inc. doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


Loading graphics...

Worst Drawdowns

The table below displays the maximum drawdowns of the Bio-Rad Laboratories, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Bio-Rad Laboratories, Inc. was 83.64%, occurring on Aug 19, 1982. Recovery took 906 trading sessions.

The current Bio-Rad Laboratories, Inc. drawdown is 66.24%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-83.64%Mar 4, 1980623Aug 19, 1982906Mar 20, 19861529
-73.77%Sep 3, 2021939Jun 2, 2025
-68.75%Feb 17, 19871740Dec 31, 1993343May 11, 19952083
-50.88%Aug 12, 2008144Mar 9, 2009277Apr 14, 2010421
-48.44%Jun 13, 1996681Feb 24, 1999484Jan 24, 20011165

Volatility

Volatility Chart

The chart below shows the rolling one-month volatility.


Loading graphics...

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Bio-Rad Laboratories, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.


Annual
Quarterly

0.0

Valuation

The Valuation section provides an overview of how Bio-Rad Laboratories, Inc. is priced in the market compared to other companies in the Medical Devices industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.


PE Ratio

The chart displays the Price-to-Earnings (P/E) ratio for BIO, comparing it with other companies in the Medical Devices industry. Currently, BIO has a P/E ratio of 9.9. This P/E ratio is considered low compared to industry peers, which may suggest that the stock is undervalued or that the company has weaker growth prospects.

PEG Ratio

The chart shows the Price/Earnings to Growth (PEG) ratio for BIO compared to other companies in the Medical Devices industry. BIO currently has a PEG ratio of 0.1. This PEG ratio is low compared to industry peers, which could indicate the stock is undervalued relative to its expected growth.

PS Ratio

This chart shows the Price-to-Sales (P/S) ratio for BIO relative to other companies in the Medical Devices industry. Currently, BIO has a P/S ratio of 2.9. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.

PB Ratio

The chart illustrates the Price-to-Book (P/B) ratio for BIO in comparison with other companies in the Medical Devices industry. Currently, BIO has a P/B value of 1.0. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items